NO942867L - Syntetisk haemophilus influenzae konjugat-vaksine - Google Patents

Syntetisk haemophilus influenzae konjugat-vaksine

Info

Publication number
NO942867L
NO942867L NO942867A NO942867A NO942867L NO 942867 L NO942867 L NO 942867L NO 942867 A NO942867 A NO 942867A NO 942867 A NO942867 A NO 942867A NO 942867 L NO942867 L NO 942867L
Authority
NO
Norway
Prior art keywords
synthetic
haemophilus influenzae
conjugate vaccine
influenzae conjugate
vaccine
Prior art date
Application number
NO942867A
Other languages
English (en)
Norwegian (no)
Other versions
NO942867D0 (enExample
Inventor
Pele Chong
Ali Kandil
Charles Sia
Michel H Klein
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of NO942867D0 publication Critical patent/NO942867D0/no
Publication of NO942867L publication Critical patent/NO942867L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/851—Haemophilus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
NO942867A 1992-02-03 1994-08-02 Syntetisk haemophilus influenzae konjugat-vaksine NO942867L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929202219A GB9202219D0 (en) 1992-02-03 1992-02-03 A synthetic heamophilus influenzae conjugate vaccine
PCT/CA1993/000041 WO1993015205A2 (en) 1992-02-03 1993-02-03 Synthetic haemophilus influenzae conjugate vaccine

Publications (2)

Publication Number Publication Date
NO942867D0 NO942867D0 (enExample) 1994-08-02
NO942867L true NO942867L (no) 1994-10-03

Family

ID=10709711

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942867A NO942867L (no) 1992-02-03 1994-08-02 Syntetisk haemophilus influenzae konjugat-vaksine

Country Status (11)

Country Link
US (3) US6018019A (enExample)
EP (1) EP0625203A1 (enExample)
JP (4) JP3421337B2 (enExample)
KR (1) KR100246122B1 (enExample)
AU (1) AU669354B2 (enExample)
CA (1) CA2129101C (enExample)
FI (1) FI943591A7 (enExample)
GB (1) GB9202219D0 (enExample)
NO (1) NO942867L (enExample)
RU (1) RU2141527C1 (enExample)
WO (1) WO1993015205A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924473D0 (en) * 1989-10-31 1989-12-20 Connaught Lab Outer membrane protein p1 and peptides of haemophilus influenzae b
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US6242578B1 (en) * 1994-02-17 2001-06-05 Samuel Bogoch Aglyco products and methods of use
US5532405A (en) * 1994-04-29 1996-07-02 Exxon Chemical Patents Inc. Preparation of plasticizer or polyol esters by the staged addition of the lower boiling point reactant
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6267961B1 (en) * 1996-11-22 2001-07-31 Baxter International Inc. Direct methods for molar-mass determination of fragments of Haemophilus influenzae type b capsular polysaccharides and vaccine preparation
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
EP0969873B1 (en) * 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US5972339A (en) * 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
JP2001523647A (ja) * 1997-11-18 2001-11-27 メディカル ユニバーシティー オブ サウス カロライナ 直鎖状抗原支持単位
DE69927369T2 (de) * 1998-04-15 2006-06-22 Mayo Foundation For Medical Education And Research, Rochester Hemmung xenoreaktiver antikörper
JP2002532115A (ja) * 1998-12-19 2002-10-02 エムエル ラボラトリーズ ピーエルシー 異種移植片に対する寛容の改善
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
ES2329651T3 (es) * 2000-03-01 2009-11-30 Binax, Inc. Metodo para detectar la presencia de una bacteria objetivo y un antigeno de carbohidrato de la misma.
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7442761B2 (en) 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
NZ592340A (en) * 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
US20040043419A1 (en) * 2001-04-17 2004-03-04 Rothman James E. Javelinization of protein antigens to heat shock proteins
WO2002098368A2 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ES2535451T3 (es) 2002-08-12 2015-05-11 The Council Of The Queensland Institute Of Medical Research Nuevos lipopéptidos inmunógenos que comprenden epítopos de linfocitos T auxiliares y de linfocitos T citotóxicos (CTL)
US7569225B2 (en) * 2002-08-12 2009-08-04 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and B-cell epitopes
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2004091493A2 (en) * 2003-04-11 2004-10-28 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
EP2092059A4 (en) * 2006-10-24 2012-03-28 Bogoch Samuel METHOD FOR FORECASTING INFLUENZA EXCESSIONS BY CORRELATION OF AN INCREASED REPLICINE MIRROR IN WHITE SPOT AND / OR TAURA VIRUSES IN CRABES
US20090017052A1 (en) * 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
MX2009013091A (es) * 2007-05-30 2010-07-30 Bogoch Samuel Peptidos de repliquina sinteticos contra infeccion patogenica de invertebrados en acuicultura.
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
WO2010079739A1 (ja) * 2009-01-07 2010-07-15 大塚製薬株式会社 全インフルエンザ菌の測定方法
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2501403A4 (en) * 2009-11-16 2013-11-13 Jackson H M Found Military Med ANTI-GRAM-POSITIVE BACTERIAL VACCINE ON (POLY) GLYCEROL PHOSPHATE BASE
WO2012170356A1 (en) * 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
US10376571B2 (en) * 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
HK1225739A1 (zh) * 2013-12-03 2017-09-15 Virometix Ag 针对肺炎链球菌进行保护的富含脯氨酸的肽
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
CN105585633B (zh) * 2016-03-08 2019-06-21 湖北工业大学 抗人流感嗜血杆菌p6蛋白抗体及应用该抗体的免疫层析试剂盒
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
BR112021000455A2 (pt) 2018-07-12 2021-04-06 Hexamer Therapeutics, Inc. Suporte de peptídeo de automontagem
EP3908669A4 (en) 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
WO2021081485A1 (en) 2019-10-25 2021-04-29 Northwestern University Cell-free extract preparation protocol for enrichment of membrane vesicles and increased glycoprotein yields
JP2023542141A (ja) * 2020-09-15 2023-10-05 ザ ユニバーシティー オブ モンタナ 繊維状バクテリオファージを標的化する組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens
EP0320942A3 (en) * 1987-12-18 1989-10-04 American Cyanamid Company Novel polysaccharides novel macromolecular conjugates of the polysaccharides
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
EP0378929A3 (en) * 1988-12-23 1990-08-01 Connaught Laboratories Limited Membrane proteins and peptides of haemophilus influenzae type b
ES2081864T3 (es) * 1989-03-29 1996-03-16 Univ New York State Res Found Metodo para purificar una proteina de la membrana exterior de haemophilus influenzae.
WO1990011778A1 (en) * 1989-04-12 1990-10-18 The Rockefeller University Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine
GB8924473D0 (en) * 1989-10-31 1989-12-20 Connaught Lab Outer membrane protein p1 and peptides of haemophilus influenzae b
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B

Also Published As

Publication number Publication date
CA2129101A1 (en) 1993-08-05
JP3421337B2 (ja) 2003-06-30
CA2129101C (en) 2004-08-10
KR950700416A (ko) 1995-01-16
FI943591L (fi) 1994-09-28
JP2001064201A (ja) 2001-03-13
GB9202219D0 (en) 1992-03-18
US5679352A (en) 1997-10-21
KR100246122B1 (ko) 2000-03-15
NO942867D0 (enExample) 1994-08-02
JP2006131642A (ja) 2006-05-25
FI943591A7 (fi) 1994-09-28
RU94040386A (ru) 1996-05-10
AU3446993A (en) 1993-09-01
WO1993015205A3 (en) 1994-03-03
AU669354B2 (en) 1996-06-06
RU2141527C1 (ru) 1999-11-20
US6018019A (en) 2000-01-25
JPH07505522A (ja) 1995-06-22
EP0625203A1 (en) 1994-11-23
WO1993015205A2 (en) 1993-08-05
US5972349A (en) 1999-10-26
FI943591A0 (fi) 1994-08-02
JPH11269188A (ja) 1999-10-05

Similar Documents

Publication Publication Date Title
FI943591L (fi) Synteettinen hemofilus-influenssa yhdistelmärokote
FI914241A7 (fi) Rokotteita ei-tyypitettävää Haemophilus influenzae-bakteereja vastaan
DE69126606D1 (de) Vakzine
PT99476A (pt) Fecho de correr
FI921267L (fi) Polyetylen-proteinkonjugater
GB9015908D0 (en) Multivalent immunoglobulin
FI951979L (fi) Ryhmän B Streptococcusten vastaiset konjugaattirokotteet
IL99097A0 (en) Haemophilus paragallinarum vaccine
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
FI925032L (fi) Vaccinsammansaettningar
NO924398D0 (no) Setetrekk
GB2245019B (en) Retaining clips
BR9406589A (pt) Vacina contra doença causada por haemophilus influenzae não tipificável
GB9101182D0 (en) Tile clips
EP0647139A4 (en) CONJUGATE VACCINE FROM ADHESINE OLIGOSACCHARIDE AGAINST -i (HEMOPHILUS IN FLUENZA).
ATA27191A (de) Stromabnehmer
NO924751D0 (no) Prp-overproduserende haemophilus influenzae-stamme
GB9107227D0 (en) Clips
FI931213A0 (fi) Syntetiska med mineralfibrer foerstaerkta polymerer
GB9020584D0 (en) Vaccine
SG48106A1 (en) Pneumococcal polyaccharide conjugate vaccine
PL285447A2 (en) Hair clip
GB9019726D0 (en) Synthetic peptide vaccines
ZA907863B (en) Vaccine conjugate
ZA916490B (en) Footrot vaccine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application